Skip to main content
Erschienen in: Cancer Causes & Control 9/2007

01.11.2007 | Original Paper

Protection of mammography screening against death from breast cancer in women aged 40–64 years

verfasst von: Sandra A. Norman, A. Russell Localio, Anita L. Weber, Ralph J. Coates, Lan Zhou, Leslie Bernstein, Kathleen E. Malone, Polly A. Marchbanks, Linda K. Weiss, Nancy C. Lee, Marion R. Nadel

Erschienen in: Cancer Causes & Control | Ausgabe 9/2007

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study assessed the efficacy of community-based screening mammography in protecting against breast cancer death, asking whether age differences in efficacy persisted in the 1990s.

Methods

In a case–control study with follow-up, odds ratios (OR) were used to estimate the relative mortality rates from invasive breast cancer among women with at least one screening mammogram in the two years prior to a baseline reference date compared to non-screened women, adjusting for potential confounding. The multicenter population-based study included 553 black and white women diagnosed during 1994–1998 who died in the following five years, and 4016 controls without breast cancer.

Results

Efficacy for reducing the rate of breast cancer death within five years after diagnosis was greater at ages 50–64 years (OR = 0.47, 95% confidence interval (CI) 0.35–0.63) than at ages 40–49 (OR = 0.89, 95% CI 0.65–1.23), and greater among postmenopausal (OR = 0.45, 95% CI 0.33–0.62) than premenopausal women (OR = 0.74, 95% CI 0.53–1.04). Estimates of efficacy were conservative, as shown by sensitivity analyses addressing whether cancer was discovered by a screening mammogram, age at which screening was received, the length of the screening observation window, and years of follow-up after diagnosis.

Conclusions

Despite the persistence of age differences in efficacy of mammography screening, with greater observed benefit for women aged 50–64 years, these findings support current screening recommendations for women 40–64 years old.
Fußnoten
1
ORs and 95% CIs for late-stage disease differ slightly from those in Norman et al. [15] because 11 cases aged 40–49 years and eight cases aged 50–64 years with diagnosis of late-stage disease were added to the data set.
 
Literatur
1.
Zurück zum Zitat Humphrey LL, Helfand M, Chan BKS, Woolf SH (2002) Breast cancer screening: a summary of the evidence. Ann Intern Med 137:347–360PubMed Humphrey LL, Helfand M, Chan BKS, Woolf SH (2002) Breast cancer screening: a summary of the evidence. Ann Intern Med 137:347–360PubMed
2.
Zurück zum Zitat Smith RA, Saslow D, Sawyer KA et al (2003) American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 53:141–169PubMedCrossRef Smith RA, Saslow D, Sawyer KA et al (2003) American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 53:141–169PubMedCrossRef
4.
Zurück zum Zitat Feig S, D’Orsi C, Hendrik R et al (1998) American College of Radiology guidelines for breast cancer screening. Am J Roentgenol 171:29–33 Feig S, D’Orsi C, Hendrik R et al (1998) American College of Radiology guidelines for breast cancer screening. Am J Roentgenol 171:29–33
6.
Zurück zum Zitat American College of Obstetricians and Gynecologists (2000) Primary and preventive care: periodic assessments. ACOG Committee Opinion 246. ACOG, Washington, DC American College of Obstetricians and Gynecologists (2000) Primary and preventive care: periodic assessments. ACOG Committee Opinion 246. ACOG, Washington, DC
7.
Zurück zum Zitat Smith R, Duffy S, Gabe R, Tabar L, Yen A, Chen T (2004) The randomized trials of breast cancer screening: what have we learned? Radiol Clin North Am 42:793–806PubMedCrossRef Smith R, Duffy S, Gabe R, Tabar L, Yen A, Chen T (2004) The randomized trials of breast cancer screening: what have we learned? Radiol Clin North Am 42:793–806PubMedCrossRef
8.
Zurück zum Zitat Moss S, Cuckle H, Evans A, Johns L, Waller M, Bobrow L (2006) Effect of mammography screening from age 40 years on breast cancer mortality at 10 years’ follow-up: a randomised controlled trial. Lancet 368:2053–2060PubMedCrossRef Moss S, Cuckle H, Evans A, Johns L, Waller M, Bobrow L (2006) Effect of mammography screening from age 40 years on breast cancer mortality at 10 years’ follow-up: a randomised controlled trial. Lancet 368:2053–2060PubMedCrossRef
9.
Zurück zum Zitat Demissie K, Mills O, Rhoads G (1998) Empirical comparison of the results of randomized controlled trials and case–control studies in evaluating the effectiveness of screening mammography. J Clin Epidemiol 51:81–91PubMedCrossRef Demissie K, Mills O, Rhoads G (1998) Empirical comparison of the results of randomized controlled trials and case–control studies in evaluating the effectiveness of screening mammography. J Clin Epidemiol 51:81–91PubMedCrossRef
10.
Zurück zum Zitat Eyre H, Sondik E, Smith R, Kessler L (1995) Joint meeting on the feasibility of a study of screening premenopausal women (40–49 years) for breast cancer: April 20–21, 1994. Cancer 75:1391–1403PubMedCrossRef Eyre H, Sondik E, Smith R, Kessler L (1995) Joint meeting on the feasibility of a study of screening premenopausal women (40–49 years) for breast cancer: April 20–21, 1994. Cancer 75:1391–1403PubMedCrossRef
11.
Zurück zum Zitat Elmore J, Reisch L, Barton M et al (2005) Efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst 97:1035–1043PubMedCrossRef Elmore J, Reisch L, Barton M et al (2005) Efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst 97:1035–1043PubMedCrossRef
12.
Zurück zum Zitat Hurley S, Kaldor J (1992) The benefits and risks of mammography screening for breast cancer. Epidemiol Rev 14:101–130PubMed Hurley S, Kaldor J (1992) The benefits and risks of mammography screening for breast cancer. Epidemiol Rev 14:101–130PubMed
13.
Zurück zum Zitat Elwood JM, Cox B, Richardson AK (1993) The effectiveness of breast cancer screening by mammography in younger women. Online J Curr Clin Trials 23:Doc No 32 Elwood JM, Cox B, Richardson AK (1993) The effectiveness of breast cancer screening by mammography in younger women. Online J Curr Clin Trials 23:Doc No 32
14.
Zurück zum Zitat Weiss N, Lazovich D (1996) Case–control studies of screening efficacy: the use of persons newly diagnosed with cancer who later sustain an unfavorable outcome. Am J Epidemiol 143:319–322PubMed Weiss N, Lazovich D (1996) Case–control studies of screening efficacy: the use of persons newly diagnosed with cancer who later sustain an unfavorable outcome. Am J Epidemiol 143:319–322PubMed
15.
Zurück zum Zitat Norman S, Localio A, Zhou L et al (2006) Benefit of screening mammography in reducing the rate of late-stage breast cancer diagnoses. Cancer Causes Control 17:921–929PubMedCrossRef Norman S, Localio A, Zhou L et al (2006) Benefit of screening mammography in reducing the rate of late-stage breast cancer diagnoses. Cancer Causes Control 17:921–929PubMedCrossRef
17.
Zurück zum Zitat Wee C, McCarthy E, Davis R, Phillips R (2000) Screening for cervical and breast cancer: is obesity an unrecognized barrier to preventive care? Ann Intern Med 132:697–704PubMed Wee C, McCarthy E, Davis R, Phillips R (2000) Screening for cervical and breast cancer: is obesity an unrecognized barrier to preventive care? Ann Intern Med 132:697–704PubMed
18.
Zurück zum Zitat Ostbye T, Taylor DJ, Yancy WJ, Krause K (2005) Associations between obesity and receipt of screening mammography, Papanicolaou tests, and influenza vaccination: results from the Health and Retirement Study (HRS) and the Asset and Health Dynamics Among the Oldest Old (AHEAD) Study. Am J Public Health 95:1623–1630PubMedCrossRef Ostbye T, Taylor DJ, Yancy WJ, Krause K (2005) Associations between obesity and receipt of screening mammography, Papanicolaou tests, and influenza vaccination: results from the Health and Retirement Study (HRS) and the Asset and Health Dynamics Among the Oldest Old (AHEAD) Study. Am J Public Health 95:1623–1630PubMedCrossRef
21.
Zurück zum Zitat Etzioni R, Weiss N (1998) Analysis of case–control studies of screening: Impact of misspecifying the duration of detectable preclinical pathologic changes. Am J Epidemiol 148:292–297PubMed Etzioni R, Weiss N (1998) Analysis of case–control studies of screening: Impact of misspecifying the duration of detectable preclinical pathologic changes. Am J Epidemiol 148:292–297PubMed
22.
Zurück zum Zitat Hosek R, Flanders W, Sasco A (1996) Bias in case–control studies of screening effectiveness. Am J Epidemiol 143:193–201PubMed Hosek R, Flanders W, Sasco A (1996) Bias in case–control studies of screening effectiveness. Am J Epidemiol 143:193–201PubMed
23.
Zurück zum Zitat Kerlikowske K, Grady D, Rubin S, Sandrock D, Ernster V (1995) Efficacy of screening mammography: a meta-analysis. JAMA 273:149–154PubMedCrossRef Kerlikowske K, Grady D, Rubin S, Sandrock D, Ernster V (1995) Efficacy of screening mammography: a meta-analysis. JAMA 273:149–154PubMedCrossRef
24.
Zurück zum Zitat Buist D, Porter P, Lehman C, Taplin S, White E (2004) Factors contributing to mammography failure in women aged 40–49 years. J Natl Cancer Inst 96:1432–1440PubMedCrossRef Buist D, Porter P, Lehman C, Taplin S, White E (2004) Factors contributing to mammography failure in women aged 40–49 years. J Natl Cancer Inst 96:1432–1440PubMedCrossRef
25.
Zurück zum Zitat Carney P, Miglioretti D, Yankaskas B et al (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138:168–175PubMed Carney P, Miglioretti D, Yankaskas B et al (2003) Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138:168–175PubMed
26.
Zurück zum Zitat Stone J, Gunasekara A, Martin L, Yaffe M, Minkin S, Boyd N (2003) The detection of change in mammographic density. Cancer Epidemiol Biomarkers Prev 12:625–630PubMed Stone J, Gunasekara A, Martin L, Yaffe M, Minkin S, Boyd N (2003) The detection of change in mammographic density. Cancer Epidemiol Biomarkers Prev 12:625–630PubMed
27.
Zurück zum Zitat Boyd N, Martin L, Stone J, Little L, Minkin S, Yaffe M (2002) A longitudinal study of the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev 11:1048–1053PubMed Boyd N, Martin L, Stone J, Little L, Minkin S, Yaffe M (2002) A longitudinal study of the effects of menopause on mammographic features. Cancer Epidemiol Biomarkers Prev 11:1048–1053PubMed
28.
Zurück zum Zitat Simpson S, Eurich D, Majumdar S et al (2006) A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333:15PubMedCrossRef Simpson S, Eurich D, Majumdar S et al (2006) A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333:15PubMedCrossRef
29.
Zurück zum Zitat American Cancer Society (2005) ACS expert disputes methodology of study questioning mammography benefit. CA Cancer J Clin 55:327–329 American Cancer Society (2005) ACS expert disputes methodology of study questioning mammography benefit. CA Cancer J Clin 55:327–329
30.
Zurück zum Zitat Duffy S, Smith R, Tabar L (2005) Re: efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst 97:1703PubMed Duffy S, Smith R, Tabar L (2005) Re: efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst 97:1703PubMed
31.
Zurück zum Zitat Elmore J, Weiss N, Barlow W et al (2005) Response Re: efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst 97:1704–1705 Elmore J, Weiss N, Barlow W et al (2005) Response Re: efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst 97:1704–1705
32.
Zurück zum Zitat Harris R (2005) Effectiveness: the next question for breast cancer screening. J Natl Cancer Inst 97:1021–1023PubMedCrossRef Harris R (2005) Effectiveness: the next question for breast cancer screening. J Natl Cancer Inst 97:1021–1023PubMedCrossRef
33.
Zurück zum Zitat Harris R (2005) Response Re: efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst 97:1703–1704 Harris R (2005) Response Re: efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst 97:1703–1704
34.
Zurück zum Zitat Paci E, Zappa M (2005) Re: efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst 97:1704PubMed Paci E, Zappa M (2005) Re: efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst 97:1704PubMed
35.
Zurück zum Zitat Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer-Verlag, New York Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer-Verlag, New York
37.
Zurück zum Zitat Tabar L, Fagerberg G, Chen H, Duffy S, Gad A (1995) Screening for breast cancer in women aged under 50: mode of detection, incidence, fatality, and histology. J Med Screen 2:94–98PubMed Tabar L, Fagerberg G, Chen H, Duffy S, Gad A (1995) Screening for breast cancer in women aged under 50: mode of detection, incidence, fatality, and histology. J Med Screen 2:94–98PubMed
38.
Zurück zum Zitat Blackman D, Bennett E, Miller D (1999) Trends in self-reported use of mammograms (1989–1997) and Papanicolaou tests (1991–1997) – Behavioral Risk Factor Surveillance System. MMWR 48:1–22 Blackman D, Bennett E, Miller D (1999) Trends in self-reported use of mammograms (1989–1997) and Papanicolaou tests (1991–1997) – Behavioral Risk Factor Surveillance System. MMWR 48:1–22
39.
Zurück zum Zitat National Center for Health Statistics (2005) Health, United States, 2005 with chartbook on trends in the health of Americans. National Center for Health Statistics, Hyattsville, MD National Center for Health Statistics (2005) Health, United States, 2005 with chartbook on trends in the health of Americans. National Center for Health Statistics, Hyattsville, MD
40.
Zurück zum Zitat Marchbanks PA, McDonald JA, Wilson HG et al (2002) The NICHD Women’s Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol 12:213–221PubMedCrossRef Marchbanks PA, McDonald JA, Wilson HG et al (2002) The NICHD Women’s Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol 12:213–221PubMedCrossRef
41.
Zurück zum Zitat Norman SA, Localio AR, Zhou L et al (2003) Validation of self-reported screening mammography histories among women with and without breast cancer. Am J Epidemiol 158:264–271PubMedCrossRef Norman SA, Localio AR, Zhou L et al (2003) Validation of self-reported screening mammography histories among women with and without breast cancer. Am J Epidemiol 158:264–271PubMedCrossRef
42.
Zurück zum Zitat Duffy SW, Day NE, Tabar L, Chen H-H, Smith T (1997) Markov models of breast tumor progression: some age-specific results. Monogr Natl Cancer Inst 22:93–97PubMed Duffy SW, Day NE, Tabar L, Chen H-H, Smith T (1997) Markov models of breast tumor progression: some age-specific results. Monogr Natl Cancer Inst 22:93–97PubMed
43.
Zurück zum Zitat Shen Y, Zelen M (2001) Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncology 19:3490–3499 Shen Y, Zelen M (2001) Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncology 19:3490–3499
44.
Zurück zum Zitat Tabar L, Fagerberg G, Chen H-H et al (1995) Efficacy of breast cancer screening by age. Cancer 75:2507–2517PubMedCrossRef Tabar L, Fagerberg G, Chen H-H et al (1995) Efficacy of breast cancer screening by age. Cancer 75:2507–2517PubMedCrossRef
45.
Zurück zum Zitat Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE (2002) Longterm effects of mammography screening: updated overview and the Swedish randomised trials. Lancet 359:909–919PubMedCrossRef Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE (2002) Longterm effects of mammography screening: updated overview and the Swedish randomised trials. Lancet 359:909–919PubMedCrossRef
Metadaten
Titel
Protection of mammography screening against death from breast cancer in women aged 40–64 years
verfasst von
Sandra A. Norman
A. Russell Localio
Anita L. Weber
Ralph J. Coates
Lan Zhou
Leslie Bernstein
Kathleen E. Malone
Polly A. Marchbanks
Linda K. Weiss
Nancy C. Lee
Marion R. Nadel
Publikationsdatum
01.11.2007
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 9/2007
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-007-9006-8

Weitere Artikel der Ausgabe 9/2007

Cancer Causes & Control 9/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.